B7-H6/Cd3 T-Cell Engager Bi 765049 ± Ezabenlimab In Advanced Solid Tumors Expressing B7-H6

B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab in advanced solid tumors expressing B7-H6

Clinical Trial: BI 765049 for Cancer (NCT04752215)

Power Life Sciences

New Solid Tumors Clinical Trial: BMS-986315 for Solid Tumors, Advanced Solid Tumors

Power Life Sciences

B7-H3-CAR T cells for the treatment of pediatric adrenocortical carcinoma

BI 764532: a novel T-cell engager for patients with DLL3+ SCLC and NEC

Investigating ezabenlimab in combination with a VEGF/Ang2-blocking nanobody for advanced CRC

Phase I trial of BI 764532, a T-cell engager for DLL3-positive NEC and SCLC

Results from Phase I/II study of DS-7300a in advanced solid tumors

ctDNA MRD as a biomarker for solid tumors

Dr Jim Norman - Linking p53 and cancer spread

NCRI

Can NK Cells Persist in the Recipient?

HealthTree University for Multiple Myeloma

CLIMB360: ctDNA-based molecular screening

Clinical Trial: BI 765179 for Tumors (NCT04958239)

Power Life Sciences

Clinical Trial: INCB0123667 for Solid Tumors (NCT05238922)

Power Life Sciences

Webinar: Identifying tumor cells at the single cell level through machine learning

The future of cellular therapies for solid tumors

Producing patient-specific tumor-reactive T-cells

KIR Blockade_ Empowering NK Cells for Superior Tumor Clearance

tumor cells

Creative Bioarray

HPN328, a tri-specific T-cell engager, in SCLC and neuroendocrine cancers